share_log

6-K: Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency

6-K: Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency

6-K:Blenrep(Belantamab Mafodotin)联合疗法治疗多发性骨髓瘤的申请获欧洲药品管理局受理审查
美股sec公告 ·  07/19 07:11
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息